...
首页> 外文期刊>Journal of Pharmacy and Pharmacology >Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
【24h】

Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.

机译:FG020318在体内和体外逆转了P-gp介导的多药耐药性。

获取原文
获取原文并翻译 | 示例

摘要

Overexpression of P-glycoprotein (P-gp) by tumours results in multidrug resistance (MDR) to structurally and functionally unrelated chemotherapeutic drugs. Combined therapy with MDR-related cytotoxins and MDR modulators is a promising strategy to overcome clinical MDR. This study was performed to explore the MDR reversal activity of a novel compound 2-[4-(2-pyridin-2-yl-vinyl) phenyl]-4,5-bis-(4-N,N-diethylaminophenyl)-1(H)-imidazole (FG020318) in-vitro and in-vivo. Tetrazolium (MTT) assay was used to evaluate the ability of FG020318 to reverse drug resistance in two P-gp-expressing tumour cell lines, KBv200 and MCF-7/adr. Intracellular doxorubicin accumulation was determined by fluorescence spectrophotometry in MCF-7/adr cell line. The effect of FG020318 on P-gp function was demonstrated by rhodamine 123 (Rh123) accumulation in KBv200 cells. KBv200 cell xenograft models were established to study the in-vivo effect of FG020318 on reversing MDR. FG020318 was not cytotoxic by itself against P-gp expressing KBv200 cells and MCF-7/adr cells and their parental drug-sensitive KB cells and MCF-7 cells. FG020318 could significantly increase the sensitivity of MDR cells to antitumour drugs including doxorubicin and vincristine in MCF-7/adr cells and KBv200 cells, respectively. It was much stronger than the positive control verapamil in reversal of MDR. FG020318 also increased the intracellular accumulation of doxorubicin in a concentration-dependent manner in MCF-7/adr cells, but did not affect the accumulation of doxorubicin in drug-sensitive MCF-7 cells. The Rh123 accumulation in resistant KBv200 cells was also increased by the addition of FG020318, but Rh123 accumulation was not affected by FG020318 in drug-sensitive KB cells. FG020318 potentiated the antitumour activity of vincristine to KBv200 xenografts and was an efficacious modulator in-vivo. Our results suggested that FG020318 was a highly potent, efficacious MDR modulator not only in-vitro but also in-vivo. The reversal of drug resistance by FG020318 was probably related to the increased anticancer drug accumulation and its inhibition of P-gp function of MDR tumour cells.
机译:肿瘤过度表达P-糖蛋白(P-gp)会导致对结构和功能上不相关的化学治疗药物的多重耐药性(MDR)。与MDR相关的细胞毒素和MDR调节剂联合治疗是克服临床MDR的有前途的策略。进行了这项研究,以探索新型化合物2- [4-(2-吡啶-2-基-乙烯基)苯基] -4,5-双-(4-N,N-二乙基氨基苯基)-1的MDR逆转活性(H)-咪唑(FG020318)体外和体内。四唑(MTT)分析用于评估FG020318逆转两种表达P-gp的肿瘤细胞系KBv200和MCF-7 / adr的耐药性的能力。通过荧光分光光度法在MCF-7 / adr细胞系中测定细胞内阿霉素的积累。罗丹明123(Rh123)在KBv200细胞中的积累证明了FG020318对P-gp功能的作用。建立KBv200细胞异种移植模型以研究FG020318对逆转MDR的体内作用。 FG020318本身对表达P-gp的KBv200细胞和MCF-7 / adr细胞及其亲代药物敏感性KB细胞和MCF-7细胞没有细胞毒性。 FG020318可以分别显着提高MDR细胞对MCF-7 / adr细胞和KBv200细胞中抗肿瘤药物(包括阿霉素和长春新碱)的敏感性。在逆转MDR方面,它比阳性对照维拉帕米强得多。 FG020318还以浓度依赖的方式增加了MCF-7 / adr细胞中阿霉素的细胞内积累,但不影响药物敏感性MCF-7细胞中阿霉素的积累。通过添加FG020318也可增加耐药性KBv200细胞中Rh123的积累,但在药物敏感性KB细胞中,Rh123的积累不受FG020318的影响。 FG020318增强了长春新碱对KBv200异种移植物的抗肿瘤活性,并且是体内有效的调节剂。我们的结果表明,FG020318是一种高效,高效的MDR调节剂,不仅在体内而且在体内。 FG020318逆转耐药性可能与增加的抗癌药物蓄积及其抑制MDR肿瘤细胞的P-gp功能有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号